

=====

Sequence Listing was accepted.

If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).

Reviewer: Keisha Douglas

Timestamp: [year=2009; month=3; day=12; hr=17; min=32; sec=28; ms=593;]

=====

Application No: 10564788

Version No: 1.0

Input Set:

Output Set:

Started: 2009-02-23 11:20:49.104

Finished: 2009-02-23 11:20:51.537

Elapsed: 0 hr(s) 0 min(s) 2 sec(s) 433 ms

Total Warnings: 76

Total Errors: 0

No. of SeqIDs Defined: 76

Actual SeqID Count: 76

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)
W 213	Artificial or Unknown found in <213> in SEQ ID (13)
W 213	Artificial or Unknown found in <213> in SEQ ID (14)
W 213	Artificial or Unknown found in <213> in SEQ ID (15)
W 213	Artificial or Unknown found in <213> in SEQ ID (16)
W 213	Artificial or Unknown found in <213> in SEQ ID (17)
W 213	Artificial or Unknown found in <213> in SEQ ID (18)
W 213	Artificial or Unknown found in <213> in SEQ ID (19)
W 213	Artificial or Unknown found in <213> in SEQ ID (20)

Input Set:

Output Set:

Started: 2009-02-23 11:20:49.104
Finished: 2009-02-23 11:20:51.537
Elapsed: 0 hr(s) 0 min(s) 2 sec(s) 433 ms
Total Warnings: 76
Total Errors: 0
No. of SeqIDs Defined: 76
Actual SeqID Count: 76

Error code

Error Description

This error has occurred more than 20 times, will not be displayed

SEQUENCE LISTING

<110> Hummel, Gerd
 Locardi, Elsa
 Polakowski, Thomas
 Scharn, Dirk
 Schnatbaum, Karsten

<120> C5a Receptor Antagonists

<130> 2918-111

<140> 10564788
 <141> 2009-02-23

<150> PCT/EP04/008057
 <151> 2004-07-19

<150> DE 03016233.3
 <151> 2003-07-17

<160> 76

<170> PatentIn version 3.5

<210> 1
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> oligopeptide with antagonistic activity at the C5a receptor

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> modified with an acetyl group

<220>
 <221> MISC_FEATURE
 <222> (4)..(4)
 <223> X = beta-cyclohexylalanine

<220>
 <221> MISC_FEATURE
 <222> (7)..(7)
 <223> X = D-Ala

<400> 1

Phe Lys Ala Xaa Ala Leu Xaa Tyr
 1 5

<210> 2

<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> oligopeptide with antagonistic activity at the C5a receptor

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> modified with an acetyl group

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> X = beta-cyclohexylalanine

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> X = N-methyl(D)ala

<400> 2

Phe Lys Ala Xaa Ala Leu Xaa Arg
1 5

<210> 3
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> oligopeptide with antagonistic activity at the C5a receptor

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> modified with an ethyl group

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> X = beta-cyclohexylalanine

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> X = N-Methyl(D)ala group

<400> 3

Phe Lys Ala Xaa Ala Leu Xaa Arg
1 5

<210> 4
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> oligopeptide with antagonistic activity at the C5a receptor

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> modified with a methyl group

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> X = beta-cyclohexylalanine

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> X = phenylbutanoyl group

<400> 4

Phe Lys Pro Xaa Phe Xaa
1 5

<210> 5
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> oligopeptide with antagonistic activity at the C5a receptor

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> modified with a methyl group

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> X = beta-cyclohexylalanine group

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> X = psi-CH₂N(CH₂CH₂C₆H₅) group

<400> 5

Phe Lys Pro Xaa Xaa Arg

1 5

<210> 6

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> oligopeptide with antagonistic activity at the C5a receptor

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> modified with an acetyl group

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> X = ornithine

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> X = beta-cyclohexylalanine

<400> 6

Phe Xaa Pro Xaa Trp Arg

1 5

<210> 7

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> oligopeptide with antagonistic activity at the C5a receptor

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> modified with an acetyl group

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> X = ornithine

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> X = beta-cyclohexylalanine

<400> 7

Phe Xaa Pro Xaa Trp Phe
1 5

<210> 8

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> oligopeptide with antagonistic activity at the C5a receptor

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> modified with an acetyl group

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> X = ornithine

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> X = beta-cyclohexylalanine

<400> 8

Phe Xaa Pro Xaa Trp Met
1 5

<210> 9

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> oligopeptide with antagonistic activity at the C5a receptor

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> modified with an acetyl group

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> X = ornithine

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> X = beta-cyclohexylalanine

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> X = norleucine

<400> 9

Lys Phe Xaa Pro Xaa Trp Xaa
1 5

<210> 10
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> oligopeptide with antagonistic activity at the C5a receptor

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> X = beta-cyclohexylalanine

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> X = ornithine

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> modified with an acetyl group

<400> 10

Phe Trp Xaa Pro Xaa Phe
1 5

<210> 11
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> oligopeptide with antagonistic activity at the C5a receptor

<220>
<221> MISC_FEATURE

<222> (3)..(3)
<223> X = beta-cyclohexylalanine

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> X = ornithine

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> modified with an acetyl group

<400> 11

Phe Trp Xaa Pro Xaa Phe
1 5

<210> 12
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> oligopeptide with antagonistic activity at the C5a receptor

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> X = beta-cyclohexylalanine

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> X = ornithine

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> modified with 2 methyl groups

<400> 12

Phe Trp Xaa Pro Xaa Phe
1 5

<210> 13
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> oligopeptide with antagonistic activity at the C5a receptor

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> X = beta-cyclohexylalanine

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> X = ornithine

<400> 13

Phe Trp Xaa Pro Xaa Phe
1 5

<210> 14
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> oligopeptide with antagonistic activity at the C5a receptor

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> X = beta-cyclohexylalanine

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> X = ornithine

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> modified with a methyl group

<400> 14

Phe Trp Xaa Pro Xaa Phe
1 5

<210> 15
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> oligopeptide with antagonistic activity at the C5a receptor

<220>

<221> MISC_FEATURE
<222> (3)..(3)
<223> X = beta-cyclohexylalanine

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> X = ornithine

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> modified with a Bu-NH-CO group

<400> 15

Phe Trp Xaa Pro Xaa Phe
1 5

<210> 16
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> oligopeptide with antagonistic activity at the C5a receptor

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> X = beta-cyclohexylalanine

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> X = ornithine

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> modified with an acetyl group

<400> 16

Phe Trp Xaa Ala Xaa Phe
1 5

<210> 17
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> oligopeptide with antagonistic activity at the C5a receptor

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> X = beta-cyclohexylalanine

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> X = ornithine modified with an acetyl group

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> modified with an acetyl group

<400> 17

Phe Trp Xaa Pro Xaa Phe
1 5

<210> 18
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> oligopeptide with antagonistic activity at the C5a receptor

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> X = beta-cyclohexylalanine

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> modified with an acetyl group

<400> 18

Phe Trp Xaa Pro Trp Phe
1 5

<210> 19
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> oligopeptide with antagonistic activity at the C5a receptor

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> beta-cyclohexylalanine

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> X = ornithine

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> modified with a phenyl-NH-CO group

<400> 19

Phe Trp Xaa Pro Xaa Phe
1 5

<210> 20
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> oligopeptide with antagonistic activity at the C5a receptor

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> X = beta-cyclohexylalanine

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> X = ornithine

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> modified with a Bu-O-CO group

<400> 20

Phe Trp Xaa Pro Xaa Phe
1 5

<210> 21
<211> 6
<212> PRT
<213> Artificial Sequence

<220>

<223> oligopeptide with antagonistic activity at the C5a receptor

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> X = betacyclohexylalanine

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> modified with an acetyl group

<400> 21

Phe Trp Xaa Pro Lys Phe

1 5

<210> 22

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> oligopeptide with antagonistic activity at the C5a receptor

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> X = beta-cyclohexylalanine

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> modified with an acetyl group

<400> 22

Phe Trp Xaa Pro Arg Phe

1 5

<210> 23

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> oligopeptide with antagonistic activity at the C5a receptor

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> X = beta-cyclohexylalanine

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> modified with an acetyl group

<400> 23

Phe Trp Xaa Pro Gln Phe
1 5

<210> 24
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> oligopeptide with antagonistic activity at the C5a receptor

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> X = beta-cyclohexylalanine

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> modified with an acetyl group

<400> 24

Phe Trp Xaa Pro Trp Phe
1 5

<210> 25
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> oligopeptide with antagonistic activity at the C5a receptor

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> X = beta-cyclohexylalanine

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> modified with an acetyl group

<400> 25

Phe Trp Xaa Pro Arg Phe
1 5

<210> 26
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> oligopeptide with antagonistic activity at the C5a receptor

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> X = beta-cyclohexylalanine

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> X = ornithine

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> modified with an acetyl group

<400> 26

Phe Trp Xaa Ser Xaa Phe
1 5

<210> 27
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> oligopeptide with antagonistic activity at the C5a receptor

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> X = cyclohexylglycine

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> X = ornithine

<220>
<221> MISC_FEATURE
<222> (6)..(6)

<223> modified with an acetyl group

<400> 27

Phe Trp Xaa Pro Xaa Phe

1 5

<210> 28

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> oligopeptide with antagonistic activity at the C5a receptor

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> X = homo-cyclohexylalanine

<220>

<221> MISC_FEATURE

<222> (5)..(5)

<223> X = ornithine

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> modified with an acetyl group

<400> 28

Phe Trp Xaa Pro Xaa Phe

1 5

<210> 29

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> oligopeptide with antagonistic activity at the C5a receptor

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> X = benzothienylalanine

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> X = beta-cyclohexylalanine

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> modified with an acetyl group

<400> 29

Phe Xaa Xaa Pro Trp Phe
1 5

<210> 30
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> oligopeptide with antagonistic activity at the C5a receptor

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> modified with an acetyl group

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> X = ornithine

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> X = beta-cyclohexylalanine

<400> 30

Phe Xaa Ser Xaa Trp Phe
1 5

<210> 31
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> oligopeptide with antagonistic activity at the C5a receptor

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> modified with an acetyl group

<220>
<221> MISC_FEATURE

<222> (2)..(2)
<223> X = ornithine

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> X = cyclohexylglycine

<400> 31

Phe Xaa Pro Xaa Trp Phe
1 5

<210> 32
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> oligopeptide with antagonistic activity at the C5a receptor

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> X = benzoethienylalanine

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> X = beta-cyclohexylalanine

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> modified with an acetyl group

<400> 32

Phe Xaa Xaa Pro Arg Phe
1 5

<210> 33
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> oligopeptide with antagonistic activity at the C5a receptor

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> X = benzoethienylalanine

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> X = beta-cyclohexylalanine

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> modified with an acetamidomethyl group

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> modified with an acetyl group

<400> 33

Phe Xaa Xaa Pro Cys Phe
1 5

<210> 34
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> oligopeptide with antagonistic activity at the C5a receptor

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> modified with an acetyl group

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> X = ornithine

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> X = homo-cyclohexylalanine

<400> 34

Phe Xaa Pro Xaa Trp Phe
1 5

<210> 35
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> oligopeptide with antagonistic activity at the C5a receptor

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> X = beta-cyclohexylalanine

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> X = 2-amino-5-diethylamino-pentanoic acid

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> modified with an acetyl group

<400> 35

Phe Trp Xaa Pro Xaa Phe
1 5

<210> 36
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> oligopeptide with antagonistic activity at the C5a receptor

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> modified with an acetyl group

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> X = ornithine

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> X = beta-cyclohexylalanine

<400> 36

Phe Xaa Pro Xaa Trp Tyr
1 5

<210> 37
<211> 6

<212> PRT
<213> Artificial Sequence

<220>
<223> oligopeptide with antagonistic activity at the C5a receptor

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> X = benzothienylalanine

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> X = beta-cyclohexylalanine

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> modified with 2 methyl groups

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> modified with an acetyl group

<400> 37

Phe Xaa Xaa Pro Arg Phe
1 5

<210> 38
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> oligopeptide with antagonistic activity at the C5a receptor

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> X = benzothienylalanine

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> X = beta-cyclohexylalanine

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> modified with an acetyl group

<400> 38

Cys Phe Xaa Xaa Pro Cys Phe
1 5

<210> 39

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> oligopeptide with antagonistic activity at the C5a receptor

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> modified with an acetyl group

<220>

<221> misc_feature

<222> (2)..(2)

<223> Xaa can be any naturally occurring amino acid

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> X = beta-cyclohexylalanine

<400> 39

Phe Xaa Pro Xaa Trp Leu
1 5

<210> 40